Macrophage migration inhibitory factor (MIF) and IgA anti CD74 antibodies in Indian patients with enthesitis-related arthritis category of Juvenile idiopathic arthritis
- 30 July 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 43 (1) , 157-162
Abstract
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine and has been implicated in pathogenesis of ankylosing spondylitis (AS). CD 74 is the receptor for MIF and IgA antiCD74 autoantibodies have been described from different parts of the world in patients with AS. As enthesitis-related arthritis (ERA) is a form of juvenile spondyloarthropathy, we studied the serum and synovial fluid levels of MIF in ERA and looked for the IgA antiCD74 antibodies in patients with ERA in our population. Patients with JIA (ILAR classification) were studied. Serum MIF levels were measured by ELISA in 101 patients of ERA (synovial fluid also where available) and compared to 28 patients of other categories of JIA, 25 patients each of ankylosing spondylitis and rheumatoid arthritis, and 38 healthy controls. In addition, association of MIF with disease activity was assessed. Ig A antiCD74 antibodies were measured in sera of ERA, AS and healthy controls. Median serum MIF levels were higher in ERA [2.50 (1.20–4.85) ng/ml] than in healthy controls [0.28 (0.16–0.48); p < 0.0001] and patients with RA [1.13 (0.44–2.45); p < 0.01] MIF levels in ERA were comparable to other categories of JIA [2.63 (1.70–4.05)] and patients with AS [3.62 (0.52–6.51)]. Synovial fluid MIF levels were higher than serum levels (p < 0.01). Serum MIF level had an association with the JSpADA score (r = 0.29, p < 0.01). Serum MIF levels had no association with presence of inflammatory markers, enthesitis, inflammatory back pain or sacroiliitis. IgA AntiCD74 antibody was positive only in 3/88 (3.41%) of ERA patients and was not detected in any patients of AS or healthy controls. Patients with ERA have high MIF levels that show modest correlation with disease activity. Higher synovial fluid MIF levels suggest that it may play a role in synovitis seen in ERA. IgA antiCD74 antibodies are rarely seen in ERA.Keywords
Funding Information
- Indian Rheumatology Association
This publication has 29 references indexed in Scilit:
- High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritisAnnals of the Rheumatic Diseases, 2014
- Autoantibodies against CD74 in spondyloarthritisAnnals of the Rheumatic Diseases, 2014
- Prevalence and incidence of juvenile idiopathic arthritis: A systematic reviewJoint Bone Spine, 2014
- Profile of Indian Patients with Juvenile Onset Chronic Inflammatory Joint Disease Using the ILAR Classification Criteria for JIA: A Community-based Cohort StudyThe Journal of Rheumatology, 2010
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnnals of the Rheumatic Diseases, 2009
- Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional studyAnnals of the Rheumatic Diseases, 2007
- Association of macrophage migration inhibitory factor gene −173 G/C polymorphism with prognosis in turkish children with juvenile rheumatoid arthritisRheumatology International, 2005
- The −174G allele of the interleukin‐6 gene confers susceptibility to systemic arthritis in children: A multicenter study using simplex and multiplex juvenile idiopathic arthritis familiesArthritis & Rheumatism, 2003
- Macrophage migration inhibitory factor: a regulator of innate immunityNature Reviews Immunology, 2003
- Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic‐onset juvenile idiopathic arthritisArthritis & Rheumatism, 2003